Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT04043806) enrolled 458 participants who were given a combination treatment referred to as ELX/TEZ/IVA. The trial was measuring the safety and tolerability of this treatment — in other words, it was looking at whether participants experienced any unwanted health events while taking it. Of the 458 who started, 412 completed the trial, while 46 did not finish. The reported data shows that the main (primary) outcome being tracked was the number of participants who experienced what are called "treatment-emergent adverse events" (TEAEs) — meaning any unwanted health events that appeared or worsened after starting the treatment — as well as "serious adverse events" (SAEs), which are more severe health events requiring significant medical attention. According to the results reported on ClinicalTrials.gov, 435 participants were reported as experiencing at least one treatment-emergent adverse event, and 75 participants were reported as experiencing at least one serious adverse event. No further breakdown of these numbers — such as what types of events occurred or how often — was available in the submitted data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 37983082) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Cystic Fibrosis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are currently taking part in a specific related clinical study called VX17-659-105 (also known as NCT03447262)
Who may not be able to join:
- You had a bad reaction to the study drug during the VX17-659-105 study that the doctors believe could put you at extra risk if you continued
- You are currently enrolled in another clinical trial testing an experimental drug (other than the VX17-659-105 study)
Important: The trial organisers note that there may be additional eligibility requirements beyond those listed here. Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
7 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.